Experimental Allergic Encephalomyelitis, Rat

  • Bernhard Ryffel
Part of the Monographs on Pathology of Laboratory Animals book series (LABORATORY)


At the injection site in the foot pad a chronic ulcerative lesion develops due to the adjuvant, and the regional popliteal lymph node is grossly enlarged. If supportive care is provided, most animals recover from acute experimental allergic encephalomyelitis and the extent of the central inflammatory process decreases gradually.


Multiple Sclerosis Experimental Autoimmune Encephalomyelitis Myelin Basic Protein Adoptive Transfer Experimental Allergic Encephalomyelitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adda DH, Beraud E, Depieds R (1977) Evidence for suppressor cells in Lewis rats’ experimental allergic encephalomyelitis. Eur J Immunol 7: 620–623CrossRefPubMedGoogle Scholar
  2. Antel J, Oger JJ, Jackevicius S, Kuo HH, Arnason BGW (1982) Modulation of T-lymphocyte differentiation antigens: potential relevance for multiple sclerosis. Proc Natl Acad Sci USA 79: 3330–3334CrossRefPubMedGoogle Scholar
  3. Arnon R (1981) Experimental allergic encephalomyelitis: susceptibility and suppression. Immunol Rev 55: 5–30CrossRefPubMedGoogle Scholar
  4. Ben-Nun A, Cohen IR (1981) Vaccination against autoimmune encephalomyelitis (EAE): attenuated autoimmune T lymphocytes confer resistance to induction of active EAE but not to EAE mediated by the intact T lymphocyte line. Eur J Immunol 11: 949–952CrossRefPubMedGoogle Scholar
  5. Ben-Nun A, Cohen IR (1982) Experimental autoimmune encephalomyelitis (EAE) mediated by T cell lines: process of selection of lines and characterization of the cells. J Immunol 129: 303–308PubMedGoogle Scholar
  6. Ben-Nun A, Ron Y, Cohen IR (1980) Spontaneous remission of autoimmune encephalomyelitis is inhibited by splenectomy, thymectomy or ageing. Nature 288: 389–390CrossRefPubMedGoogle Scholar
  7. Ben-Nun A, Wekerle H, Cohen IR (1981) The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 11:195–199CrossRefPubMedGoogle Scholar
  8. Bolton C, Borel JF, Cuzner ML, Davison AN, Turner AM (1982a) Immunosuppression by cyclosporin A of experimental allergic encephalomyelitis. J Neurol Sci 56:147–153CrossRefPubMedGoogle Scholar
  9. Bolton C, Allsopp G, Cuzner ML (1982b) The effect of cyclosporin A on the adoptive transfer of experimental allergic encephalomyelitis in the Lewis rat. Clin Exp Immunol 47:127–132PubMedGoogle Scholar
  10. Bolton C, Borel JF, Cuzner ML, Davison AN, Turner AM (1982c) Autoimmunity: cyclosporin A therapy in experimental allergic encephalomyelitis. In: White DJG (ed) Cyclosporin A. Elsevier Biomedical, Amsterdam, pp 135–142Google Scholar
  11. Borel JF (1981) Pharmacology and pharmacokinetics of cyclosporin A. In: Touraine JL et al. (eds) Transplantation and clinical immunology, vol 13. Excerpta Medica, Amsterdam, pp 3–6Google Scholar
  12. Borel JF (ed) (1986) Cyclosporin. Prog Allergy 38: 9–18Google Scholar
  13. Borel JF, Lafferty KJ (1983) Cyclosporine: speculation about its mechanism of action. Transplant Proc 15: 1881–1885Google Scholar
  14. Borel JF, Feurer C, Gubler HU, Stahelin H (1976) Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6: 468–475CrossRefPubMedGoogle Scholar
  15. Bowern N, Ramshaw IA, Clark IA, Doherty PC (1984) Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent. J Exp Med 160:1532–1543CrossRefPubMedGoogle Scholar
  16. Brandriss MW (1963) Methotrexate: suppression of experimental allergic encephalomyelitis. Science 140: 186–187CrossRefPubMedGoogle Scholar
  17. Brosnan CF, Wisniewski HM (1980) Immunopathology of allergic encephalomyelitis. In: Batistin L, Hashim G, Lajtha A (eds) Neurochemistry and clinical neurology. Liss, New York, pp 379–390 (Progress in clinical and biological research series, vol 39)Google Scholar
  18. Brosnan CF, Cammer W, Norton WT, Bloom BR (1980) Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis. Nature 285: 235–237CrossRefPubMedGoogle Scholar
  19. Brosnan CF, Bornstein MB, Bloom BR (1981) The effects of macrophage depletion on the clinical and pathologic expression of experimental allergic encephalomyelitis. J Immunol 126: 614–620PubMedGoogle Scholar
  20. Brosnan CF, Goldmuntz EA, Cammer W, Factor SM, Bloom BR, Norton WT (1985) Prazosin, an (alpha)r adrenergic receptor antagonist, suppresses experimental autoimmune encephalomyelitis in the Lewis rat. Proc Natl Acad Sci USA 82: 5915–5919CrossRefPubMedGoogle Scholar
  21. Brosnan CF, Sacks HJ, Goldschmidt RC, Goldmuntz EA, Norton WT (1986) Prazosin treatment during the effector stage of disease suppresses experimental autoimmune encephalomyelitis in the Lewis rat. J Immunol 137:3451–3456PubMedGoogle Scholar
  22. Brown A, McFarlin DE, Raine CS (1982) Chronologic neuropathology of relapsing experimental allergic encephalomyelitis in the mouse. Lab Invest 46:171–185PubMedGoogle Scholar
  23. Cammisuli S, Feurer C (1984) The effect of cyclosporin-A and dihydrocyclosporin-D on the therapy and prophylaxis of experimental allergic encephalomyelitis. Prog Clin Biol Res 146: 415–421PubMedGoogle Scholar
  24. Davison AN, Cuzner ML (1980) The suppression of experimental allergic encephalomyelitis and multiple sclerosis. Academic, LondonGoogle Scholar
  25. DeFreitas EC, Sandberg-Wollheim M, Schonely K, Boufal M, Koprowski H (1986) Regulation of interleukin 2 receptors on T cells from multiple sclerosis patients. Proc Natl Acad Sci USA 83: 2637–2641CrossRefPubMedGoogle Scholar
  26. Feurer C, Prentice DE, Cammisuli S (1985) Chronic relapsing experimental allergic encephalomyelitis in the Lewis rat. J Neuroimmunol 10:159–166CrossRefPubMedGoogle Scholar
  27. Fontana A, Fierz W, Wekerle H (1984) Astrocytes present myelin basic protein to encephalitogenic T-cell lines. Nature 307: 273–276CrossRefPubMedGoogle Scholar
  28. Fredane LM, Hashim GA, McCabe RE (1983) The effect of cyclosporine on lymphocyte subsets in experimental allergic encephalomyelitis. Functional loss of diseasesuppressing cells in vivo. Transplant Proc (Suppl) 15: 2909–2913Google Scholar
  29. Fritz RB, Chou CHJ, McFarlin DE (1983) Relapsing murine allergic encephalomyelitis induced by myelin basic protein. J Immunol 130:1024–1026PubMedGoogle Scholar
  30. Goldmuntz EA, Brosnan CF, Norton WT (1986) Prazosin treatment suppresses increased vascular permeability in both acute and passively transferred experimental auto immune encephalomyelitis in the Lewis rat. J Immunol 137: 3444–3450PubMedGoogle Scholar
  31. Hauser SL, Weiner HL, Che M, Shapiro ME, Gilles F, Letvin NL (1984) Prevention of experimental allergic encephalomyelitis (EAE) in the SJL/J mouse by whole body ultraviolet irradiation. J Immunol 132:1276–1281PubMedGoogle Scholar
  32. Hayosh NS, Swanborg RH (1986) Autoimmune effector cells. VII. Cells isolated from thymus and spinal cord of rats with experimental allergic encephalomyelitis transfer disease. Am J Pathol 122:218–222PubMedGoogle Scholar
  33. Hickey WF, Gonatas NK (1984) Suppressor T-lymphocytes in the spinal cord of Lewis rats recovered from acute experimental allergic encephalomyelitis. Cell Immunol 85: 284–288CrossRefPubMedGoogle Scholar
  34. Hinrichs DJ, Roberts CM, Waxman FJ (1981) Regulation of paralytic experimental allergic encephalomyelitis in rats: susceptibility to active and passive disease reinduction. J Immunol 126: 1857–1862PubMedGoogle Scholar
  35. Hinrichs DJ, Wegmann KW, Peters BA (1983) The influence of cyclosporin A on the development of actively induced and passively transferred experimental allergic encephalomyelitis. Cell Immunol 77: 202–209CrossRefPubMedGoogle Scholar
  36. Holda JH, Swanborg RH (1981) Regulation of experimental allergic encephalomyelitis. III. Demonstration of effector cells in tolerant rats. Eur J Immunol 11: 338–340CrossRefPubMedGoogle Scholar
  37. Hommes OR, Lamers KJB, Reekers P (1980) Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis. J Neurol 223:177–190CrossRefGoogle Scholar
  38. Hoyer LW, Good RA, Condie RM (1962) Experimental allergic encephalomyelitis: the effect of 6-mercaptopurine. J Exp Med 116: 311–327CrossRefPubMedGoogle Scholar
  39. Kabat EA, Wolf A, Bezer AE (1952) Studies on acute disseminated encephalomyelitis produced experimentally in rhesus monkeys. VII. Effect of cortisone. J Immunol 68:265–275PubMedGoogle Scholar
  40. Keith AB (1978) Sex difference in Lewis rats in the incidence of recurrent experimental allergic encephalomyelitis. Nature 272: 824–825CrossRefPubMedGoogle Scholar
  41. Lemire JM, Weigle WO (1986) Passive transfer of experimental allergic encephalomyelitis by myelin basic protein-specific L3T4+ T cell clones possessing several functions. J Immunol 137: 3169–3174PubMedGoogle Scholar
  42. Linthicum DS, Munoz JJ, Blaskett A (1982) Acute experimental autoimmune encephalomyelitis in mice. I. Adjuvant action of Bordetella pertussis is due to vasoactive amine sensitization and increased vascular permeability of the central nervous system. Cell Immunol 73: 299–310CrossRefPubMedGoogle Scholar
  43. Lublin FD, Maurer PH, Berry RG, Tippett D (1981) Delayed, relapsing, experimental allergic encephalomyelitis in mice. J Immunol 126: 819–822PubMedGoogle Scholar
  44. McCarron RM, Spatz M, Kempski O, Hogan RN, Muehl L, McFarlin DE (1986) Interaction between myelin basic protein-sensitized T lymphocytes and murine cerebral vascular endothelial cells. J Immunol 137: 3428–3435PubMedGoogle Scholar
  45. McFarlin DE, McFarland HF (1982) Multiple sclerosis. N Engl J Med 307:1183–1188,1246-1251CrossRefPubMedGoogle Scholar
  46. McFarlin D, Blank SE, Kibler RF (1974) Recurrent experimental allergic encephalomyelitis in the Lewis rat. J Immunol 113:712–715PubMedGoogle Scholar
  47. McKhann GM (1982) Multiple sclerosis. Annu Rev Neurosci 5: 219–239CrossRefPubMedGoogle Scholar
  48. Mokhtarian F, McFarlin D, Raine CS (1984) Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature 309: 356–359CrossRefPubMedGoogle Scholar
  49. Paterson PY (1978) Autoimmune neurological disease: experimental animal systems and implications for multiple sclerosis. In: Talal N (ed) Autoimmunity: genetic, immunologic, virologic and clinical aspects. Academic, New York, pp 644–691Google Scholar
  50. Paterson PY, Beisaw NE (1963) Effect of whole body xirradiation on induction of allergic encephalomyelitis in rats. J Immunol 90: 532–539PubMedGoogle Scholar
  51. Paterson PY, Drobish DG (1969) Cyclosphosphamide. Effect on experimental allergic encephalomyelitis in Lewis rats. Science 165:191–192CrossRefPubMedGoogle Scholar
  52. Paterson PY, Hanson MA (1969) Cyclophosphamide inhibition of experimental allergic encephalomyelitis and cellular transfer of the disease in Lewis rats. J Immunol 103:1311–1316PubMedGoogle Scholar
  53. Peters BA, Hinrichs DJ (1982) Passive transfer of experimental allergic encephalomyelitis in the Lewis rat with activated spleen cell: differential activation with mitogens. Cell Immunol 69: 175–185CrossRefPubMedGoogle Scholar
  54. Raine CS (1984) Biology of disease. Analysis of autoimmune demyelination: its impact upon multiple sclerosis. Lab Invest 50: 608–635PubMedGoogle Scholar
  55. Raine CS, Stone SH (1977) Animal model for multiple sclerosis: chronic experimental allergic encephalomyelitis in inbred guinea pigs. NY State J Med 77: 1693–1696Google Scholar
  56. Raine CS, Mokhtarian F, McFarlin DE (1984) Adoptively transferred chronic relapsing experimental autoimmune encephalomyelitis in the mouse. Neuropathologic analysis. Lab Invest 51: 534–546PubMedGoogle Scholar
  57. Ryffel B, Feurer C, Heuberger B, Borel JF (1982) Immunosuppressive effect of cyclosporin A in two lymphocyte transfer models in rats: comparison of in vivo and in vitro treatment. Immunobiology 163: 470–483CrossRefPubMedGoogle Scholar
  58. Saka K, Namikawa T, Kunishita T, Yamanouchi K, Tabira T (1986) Studies of experimental allergic encephalomyelitis by using encephalitogenic T cell lines and clones in euthymic and athymic mice. J Immunol 137: 1527–1531Google Scholar
  59. Schluesener HJ, Lassmann H (1985) Recombinant interleukin 2 (IL-2) promotes T cell line-mediated neuroautoimmune disease. J Neuroimmunol 11: 87–91CrossRefGoogle Scholar
  60. Schnyder B, Weber E, Fierz W, Fontana A (1986) On the role of astrocytes in polyclonal T cell activation. J Neuroimmunol 10: 209–218CrossRefPubMedGoogle Scholar
  61. Schuller-Levis GB, Kozlowski PB, Wisniewski HM (1986) Cyclosporin A treatment of an induced attack in a chronic relapsing model of experimental allergic encephalomyelitis. Clin Immunol Immunopathol 40: 244–252CrossRefPubMedGoogle Scholar
  62. Sobel RA, Blanchette BW, Bhan AK, Colvin RB (1984) The immunopathology of experimental allergic encephalomyelitis. I. Quantitative analysis of inflammatory cells in situ. J Immunol 132: 2393–2401PubMedGoogle Scholar
  63. Steinman L, Rosenbaum JT, Sriram S, McDevitt HO (1981) In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. Proc Natl Acad Sci USA 78: 7111–7114CrossRefPubMedGoogle Scholar
  64. Stone SH, Traugott U, Raine CS (1983) Chronic experimental allergic encephalomyelitis in strain 2 guinea pigs: absence of resistance to nervous system changes and sex dependence of clinical disease. J Neuroimmunol 4:187–199CrossRefPubMedGoogle Scholar
  65. Traugott U, Stone SH, Raine CS (1979) Chronic relapsing experimental allergic encephalomyelitis. Correlation of circulating lymphocyte fluctuations with disease activity in suppressed and unsuppressed animals. J Neurol Sci 41:17–29CrossRefPubMedGoogle Scholar
  66. Traugott U, Shevach E, Chiba J, Stone SH, Raine CS (1982) Chronic relapsing experimental allergic encephalomyelitis: identification and dynamics of T and B cells within the central nervous system. Cell Immunol 68:261–275CrossRefPubMedGoogle Scholar
  67. Vandenbark AA, Raus JCM (eds) (1984) Immunoregulatory processes in experimental allergic encephalomyelitis and multiple sclerosis. Research monographs in immunology. Elsevier, AmsterdamGoogle Scholar
  68. Waldor MK, Sriram S, Hardy R, Herzenberg LA, Herzenberg LA, Lanier L, Lim M, Steinman L (1985) Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Science 227: 415–417CrossRefPubMedGoogle Scholar
  69. Waxman FJ, Taguiam JM, Whitacre CC (1984) Modification of the clinical and histopathologic expression of experimental allergic encephalomyelitis by the vasoactive amine antagonist cyproheptadine. Cell Immunol 85: 82–93CrossRefPubMedGoogle Scholar
  70. Weigle WO (1980) Analysis of autoimmunity through experimental models of thyroiditis and allergic encephalomyelitis. Adv Immunol 30:159–273CrossRefPubMedGoogle Scholar
  71. Wiesinger D, Borel JF (1980) Studies on the mechanism of action of cyclosporin A. Immunology 156: 454–463Google Scholar
  72. Willenborg DO, Sjollema P, Danta G (1986) Immunoglobulin deficient rats as donors and recipients of effector cells of allergic encephalomyelitis. J Neuroimmunol 11:93–103CrossRefPubMedGoogle Scholar
  73. Wisniewski HM, Madrid RE (1983) Chronic progressive experimental allergic encephalomyelitis (EAE) in adult guinea pigs. J Neuropathol Exp Neurol 42: 243–255CrossRefPubMedGoogle Scholar
  74. Zamvil S, Nelson P, Trotter J, Mitchell D, Knobler R, Fritz R, Steinman L (1985) T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature 317: 355–358CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • Bernhard Ryffel

There are no affiliations available

Personalised recommendations